法律意见书 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 浙江天册律师事务所 关于 华东医药股份有限公司 2024 年度股东大会的 法律意见书 浙江天册律师事务所 关于华东医药股份有限公司 2024 年度股东大会的 法律意见书 编号：TCYJS2025H0737 号 致：华东医药股份有限公司 本所律师根据《股东会规则》的要求，按照律师行业公认的业务标准、道德规 范和勤勉尽责的精神，对华东医药本次股东大会所涉及的有关事项和相关文件进 行了必要的核查和验证，同时听取了公司就有关事实的陈述和说明。现出具法律意 见如下： 一、本次股东大会召集、召开的程序 （一）经本所律师核查，公司本次股东大会由董事会提议并召集，召开本次股 东大会的通知已于 2025 年 4 月 18 日在指定媒体及深圳证券交易所网站上公告。 （二）本次股东大会采取现场投票与网络投票相结合的方式。 根据本次股东大会的会议通知，本次股东大会现场会议召开的时间为 2025 年 5 月 15 日下午 14:00-15:00；召开地点为浙江省杭州市拱墅区 ...

证券代码：000963 证券简称：华东医药 公告编号：2025-042 华东医药股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决提案情形，也不涉及变更以往股东大会 已通过决议的情形； 2、本次股东大会审议的提案8.01涉及的关联股东已回避表决。 2、召开地点：浙江省杭州市拱墅区莫干山路858号华东医药股份 有限公司新大楼3楼远大厅。 3、召开方式：现场投票与网络投票相结合的表决方式 4、召集人：公司董事会 5、主持人：公司董事长 吕梁 6、本次会议召集、召开与表决程序符合《公司法》《深圳证券交 易所股票上市规则》及《公司章程》等法律、法规及规范性文件的规 二、会议出席情况 1、股东出席的总体情况： 3、本次股东大会对中小股东单独计票。中小股东是指：除公司 董事、监事、高级管理人员以及单独或合计持有公司5%以上股份的股 东以外的其他股东。 一、会议召开情况 1、召开时间：2025年5月15日（星期四）下午14:00-15:00 其中：通过现场投票的中小股东29人，代表股份924,180 ...

Financial Performance - In 2024, the company achieved a revenue of CNY 41.906 billion, with a foreign sales revenue of CNY 1.095 billion, accounting for 2.61% of total revenue [20] - The pharmaceutical industrial revenue reached CNY 13.811 billion, representing 32.96% of total revenue [13] - The medical beauty business generated CNY 2.326 billion in revenue, with the subsidiary Xinkeli Meixue contributing CNY 1.139 billion [10] Business Development - The company completed its seventh three-year plan, achieving record high revenue and net profit attributable to shareholders [1] - The industrial microbiology business reported a revenue of CNY 711 million, a year-on-year increase of 43.12% [5] - The company is focusing on four strategic directions: xRNA, specialty APIs & intermediates, health & biological materials, and animal health [2] Product Pipeline and Innovation - The company is preparing for the commercial launch of the innovative ADC drug, Ailaha (Somatuzumab), targeting platinum-resistant ovarian cancer [3] - The oral GLP-1 receptor agonist HDM1002 has completed Phase III clinical trials for weight management, with over 800 participants enrolled in earlier phases [4] - The company has 15 new patent authorizations in 2024, including core patents for GLP-1R/GIPR dual-target agonists [6] Market Strategy - The company maintains a global operational layout for its medical beauty business, focusing on high-end markets [2] - The company plans to enhance its market coverage and registration processes to stabilize the performance of its core subsidiary, Sinclair [2] - The company aims to improve the accessibility of its innovative high-priced drugs through diverse payment channels and market penetration strategies [21] Challenges and Responses - The medical beauty sector faces challenges due to macroeconomic slowdowns and declining consumer demand, but is expected to stabilize with new product approvals [30] - The company is actively managing production costs and enhancing operational efficiency to mitigate the impact of drug price negotiations and procurement policies on profit margins [19] - The company is committed to maintaining a cash dividend policy while balancing strategic development and shareholder returns [12]

Core Viewpoint - The announcement highlights the promising results of the clinical trial for DR10624, a novel long-acting triple agonist developed by Zhejiang Daor Biotechnology, a subsidiary of Huadong Medicine, for treating obesity with hypertriglyceridemia, showcasing significant efficacy in reducing liver fat and improving metabolic parameters [1][2][3]. Group 1: Clinical Trial Results - DR10624 demonstrated significant reductions in liver fat content (LFC) after 12 weeks, with relative decreases of 51.9%, 77.8%, 79.0%, and 75.8% across different dosage groups compared to a placebo group reduction of 26.3% [2]. - All dosage groups of DR10624 showed statistically significant reductions in fasting triglycerides (TG) compared to the placebo [2]. - The drug also improved insulin sensitivity, with HOMA-IR reductions of -42.7% and -35.9% for the 50mg and 75mg groups, respectively, while the placebo group showed an increase of +5.77% [2]. Group 2: Drug Development and Future Prospects - The clinical trial results support the potential of DR10624 in treating severe hypertriglyceridemia and metabolic-associated fatty liver diseases [3]. - DR10624 is currently undergoing Phase II clinical trials in China for treating metabolic-associated fatty liver disease with high fibrosis risk and alcohol-related fatty liver disease, with the first subject enrolled by April 2025 [3]. - A separate Phase II trial for DR10624 in treating severe hypertriglyceridemia has completed patient enrollment, with topline results expected in Q3 2025 [3]. Group 3: Company R&D Investment - Huadong Medicine has increased its R&D investment, with a reported 2024 expenditure of 2.678 billion yuan, a 16.77% year-on-year increase, and direct R&D spending accounting for 12.91% of pharmaceutical industrial revenue [4]. - The company is actively integrating AI technology to enhance drug development and production efficiency [4]. - The release of clinical data for DR10624 marks a significant advancement in the product's development and strengthens the company's competitive position in the endocrine treatment sector [4].

Core Insights - The announcement by East China Pharmaceutical (华东医药) regarding its subsidiary Zhejiang Daer Biotechnology's (道尔生物) innovative long-acting triple agonist DR10624 has garnered significant attention due to its promising clinical trial results for treating obesity with hypertriglyceridemia [1][2][9] Group 1: Clinical Trial Results - DR10624 has shown remarkable efficacy in reducing liver fat content (LFC) in a Phase Ib/IIa clinical trial, with reductions of 51.9%, 77.8%, 79.0%, and 75.8% for the 12.5 mg, 25 mg, 50 mg, and 75 mg dosage groups respectively, compared to a placebo group reduction of 26.3% [2][4] - In subjects with baseline LFC ≥8%, the relative reductions were even more pronounced, with reductions of 58.3%, 83%, 89.2%, and 87.2% for the respective dosage groups, again significantly outperforming the placebo group [4][5] - A notable 66.7%, 88.9%, 100%, and 85.7% of subjects in the respective dosage groups achieved a relative reduction of LFC ≥50%, indicating a high likelihood of histological resolution of steatohepatitis [6] Group 2: Drug Development and Pipeline - DR10624 is currently undergoing additional clinical trials in China for treating metabolic-associated fatty liver disease with liver fibrosis and severe hypertriglyceridemia, with results expected in the third quarter of 2025 [6][9] - The company has a robust pipeline of over 80 innovative drug candidates, focusing on endocrine, autoimmune, and oncology fields, with significant advancements in GLP-1 targeted products [7][9] - The oral small molecule GLP-1 receptor agonist HDM1002 has completed its first subject enrollment for weight management in a Phase III trial, with further studies in diabetes also progressing [7][8] Group 3: Market Position and Future Outlook - East China Pharmaceutical is positioning itself as a leader in the endocrine field, with DR10624's breakthrough results and ongoing development of other GLP-1 related products enhancing its competitive edge [9] - The increasing focus on multi-target agonists, particularly those targeting GLP-1, GCGR, and FGF21R, is expected to drive future growth and innovation within the company [6][9] - The company's commitment to R&D is reflected in its significant investment, with a reported R&D expenditure of 2.678 billion yuan, marking a 16.77% year-on-year increase [8]

自愿披露关于控股子公司DR10624的临床研究结果在2025 年欧洲肝病研究学会（EASL）年会发布的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华东医药股份有限公司（以下简称"公司"）控股子公司浙 江道尔生物科技有限公司（以下简称"道尔生物"）自主研发的全球首 创（First-in-class）的靶向成纤维细胞生长因子 21 受体（Fibroblast growth factor 21 receptor，FGF21R）、胰高血糖素受体（Glucagon receptor，GCGR）和胰高血糖素样肽-1 受体（Glucagon-like peptide-1 receptor，GLP-1R）的长效三重激动剂 DR10624 在新西兰治疗肥胖合 并高甘油三脂血症的 Ib/IIa 期临床研究结果在荷兰阿姆斯特丹举办的 2025 年欧洲肝病研究学会年会（EASL Congress 2025）上首次发布。 研究结果 "DR10624, a First-In-Class, FGF21 Receptor (FGF21R)/Glucagon Receptor ...

2025 年 05 月 09 日 王睿哲 C0062@capital.com.tw 目标价(元) 47.8 公司基本信息 | 产业别 | | | | 医药生物 | | --- | --- | --- | --- | --- | | A 股价(2025/5/8) | | | | 39.03 | | 深证成指(2025/5/8) | | | | 10197.66 | | 股价 12 个月高/低 | | | | 40.8/25.63 | | 总发行股数(百万) | | | | 1754.08 | | A 股数(百万) | | | | 1751.94 | | A 市值(亿元) | | | | 683.78 | | 主要股东 | | | | 中国远大集团有 | | | | | | 限责任公司 | | | | | | (41.67%) | | 每股净值(元) | | | | 13.72 | | 股价/账面净值 | | | | 2.85 | | | 一个月 | | 三个月 一年 | | | 股价涨跌(%) | | 5.8 | 13.5 18.8 | | | 近期评等 | | | | | | 日期 | 收盘价 | | 评级 ...

医药工业稳步增长，医美板块尚待恢复：(1)公司医药工业核心子公司中美华东25Q1实现营收(含CSO业务)36.2亿 元，YOY+6.5%，录得合并归母净利8.43亿元，YOY+12.2%，创新药销售持续发力，其中CAR-T产品赛恺泽(治疗 骨髓瘤)Q1有效订单稳步增加，目前已有70余家惠民保及商保将其纳入报销范围，乌司奴单抗(治疗银屑病)去年年 末获批后已有超800家医院开具处方，预计今年销售可超过3亿元；(2)海外医美仍受到大环境影响，英国 Sinclair25Q1营收2.4亿人民币，YOY-12.3%，国内医美子公司欣可丽美学则实现营收2.5亿，YOY-1.4%，但后续高 端玻尿酸产品MaiLi Extreme5月将可上市，多功能面部皮肤管理平台PréimeDermaFacial也将于2025年内正式实现 商业化销售，重组A型肉毒毒素YY001、能量源设备V30及Ellansé伊妍仕M型等核心医美产品国内上市申请均已获 受理，有望于2026年获批，预计将会推动医美板块的业绩恢复；(3)公司医药商业板块表现稳健，25Q1营收69.3亿 元，YOY+3.2%，录得净利1.2亿元，YOY+7.3%。 毛利率回升 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000963 证券简称：华东医药 公告编号：2025-040 华东医药股份有限公司 关于参加2025年浙江辖区上市公司投资者网上集体接待日 （问题征集专题页面二维码） 暨2024年度及2025年第一季度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 华东医药股份有限公司（以下简称"公司"）2024年年度报告已于2025年4月18日发布，2025年第一季度 报告已于2025年4月25日发布。为进一步加强与投资者的互动交流，公司将参加由浙江证监局指导，浙 江上市公司协会主办，深圳市全景网络有限公司承办的"2025年浙江辖区上市公司投资者网上集体接待 日暨2024年度及2025年第一季度业绩说明会"，现将相关事项公告如下： 届时公司董事长兼总经理吕梁先生、董事会秘书陈波先生、财务负责人邱仁波先生、独立董事黄简女 士、独立董事王如伟先生、独立董事高向东女士（如有特殊情况，参会人员可能会调整）将在线就公司 2024年度及2025年第一季度业绩、公司治理、发展战略、经营状况、股权激励和可持续发展等投资 ...

关于参加2025年浙江辖区上市公司投资者网上集体接待日暨 2024年度及2025年第一季度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 华东医药股份有限公司（以下简称"公司"）2024 年年度报告已于 2025 年 4 月 18 日发布，2025 年第一季度报告已于 2025 年 4 月 25 日发 布。为进一步加强与投资者的互动交流，公司将参加由浙江证监局指 导，浙江上市公司协会主办，深圳市全景网络有限公司承办的"2025 年 浙江辖区上市公司投资者网上集体接待日暨 2024 年度及 2025 年第一季 度业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景 路演 APP，参与本次互动交流，活动时间为 2025 年 5 月 13 日（周二） 15:00-17:00。 届时公司董事长兼总经理吕梁先生、董事会秘书陈波先生、财务负 责人邱仁波先生、独立董事黄简女士、独立董事王如伟先生、独立董事 高向东女士（如有特殊情况， ...